Development Portfolio

MyeloRx is a development company advancing a portfolio of triptolide-based compounds through IND-enabling pre-clinical studies. Because the natural product triptolide itself as well as the herb from which it was derived has shown unequivocal clinical activity we believe the clinical risk is relatively low.  We are focusing on proprietary prodrugs and derivatives of the natural product triptolide for oncology and immune-diseases. Triptolide is functionally similar to rapamycin (Rapamune®) and paclitaxel (Taxol®, Taxotere®), two approved natural products, in that each of these has anti-cancer and immune suppressant properties, however, triptolide has a different mechanism of action.